Elutia (NASDAQ:ELUT) Posts Earnings Results, Hits Expectations

Elutia (NASDAQ:ELUT) posted its quarterly earnings data on Wednesday. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14), Zacks reports. The company had revenue of $3.30 million for the quarter, compared to the consensus estimate of $3.30 million.

Here are the key takeaways from Elutia’s conference call:

• Elutia submitted NXT-41 to the FDA and expects clearance in the second half of 2026, with the drug‑eluting NXT-41X targeted for clearance toward the end of H1 2027 and a planned commercial launch in H2 2027.
• NXT-41X combines the NXT-41 biologic matrix with rifampin and minocycline to deliver uniform, local antibiotic coverage for roughly 30 days, a design intended to materially reduce postoperative breast‑reconstruction infections (management cited potential ≥~50% reductions versus current ad‑hoc local approaches).
• Management strengthened the balance sheet by selling BioEnvelope to Boston Scientific for $88 million, paying off senior debt, and ending Q4 with $44.4 million in cash plus escrow, which they say funds development through approval and commercialization.
• The company is exploring strategic options for SimpliDerm — a standalone acellular dermal product with reimbursement covering ~100 million lives — which could unlock value but would also remove an operating asset used today.
• Elutia says its Gaithersburg manufacturing facility can support ~$120 million in revenue on one shift, and the company has added commercial leadership and active KOL/VAC engagement to prepare for commercialization.

Elutia Stock Performance

Shares of NASDAQ ELUT traded up $0.02 during midday trading on Friday, hitting $1.17. 30,643 shares of the company traded hands, compared to its average volume of 265,270. Elutia has a 12-month low of $0.50 and a 12-month high of $3.46. The firm has a market cap of $49.75 million, a P/E ratio of 1.42 and a beta of 0.65. The stock has a 50-day moving average price of $0.98 and a 200 day moving average price of $0.98.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Elutia in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Elutia has a consensus rating of “Hold” and an average price target of $6.00.

Insider Buying and Selling

In other Elutia news, CFO Matthew Ferguson bought 60,000 shares of Elutia stock in a transaction dated Wednesday, December 17th. The shares were purchased at an average cost of $0.53 per share, with a total value of $31,800.00. Following the transaction, the chief financial officer directly owned 447,110 shares of the company’s stock, valued at $236,968.30. This represents a 15.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kevin Rakin purchased 70,000 shares of the stock in a transaction that occurred on Friday, January 30th. The shares were acquired at an average cost of $1.06 per share, with a total value of $74,200.00. Following the completion of the transaction, the director owned 196,120 shares in the company, valued at $207,887.20. This trade represents a 55.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 255,500 shares of company stock worth $189,605 in the last quarter. Company insiders own 27.60% of the company’s stock.

Institutional Trading of Elutia

Several institutional investors have recently bought and sold shares of the company. Deerfield Management Company L.P. bought a new position in shares of Elutia during the 3rd quarter valued at $1,221,000. XTX Topco Ltd bought a new stake in shares of Elutia in the fourth quarter worth $71,000. Citadel Advisors LLC purchased a new stake in Elutia during the third quarter valued at $50,000. Renaissance Technologies LLC lifted its holdings in Elutia by 64.7% in the fourth quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock valued at $71,000 after acquiring an additional 40,123 shares during the period. Finally, Virtu Financial LLC bought a new position in Elutia in the third quarter valued at about $26,000. 74.03% of the stock is owned by hedge funds and other institutional investors.

About Elutia

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.